Eugia Pharma Sees Three 483s Since January, Following Inspections of Plants in India

Three Eugia Pharma plants in India have received Form 483s following inspections conducted in the last two months, all laden with examples of the company failing to follow procedures to prevent microbiological contamination of its drug products, among other lapses.
Source: Drug Industry Daily